Amycretin is being developed as a next-generation treatment for obesity (and overweight), and it’s catching eyes because of how cleverly it’s built. Instead of acting on just one pathway, the molecule hits two: it activates receptors for both a gut hormone (GLP-1) and a satiety hormone (amylin). That dual effect aims to curb appetite and influence metabolism, giving it a potentially stronger, more balanced impact than older drugs.
What stands out now: early-stage trial results have been encouraging. In some studies, people on weekly injections of Amycretin lost up to 22–24 % of their body weight over roughly 36 weeks. Meanwhile, an oral pill version, handy for those who dislike injections, led to around 10–13 % weight loss over 12 weeks in initial trials.
Even among individuals with type 2 diabetes, Amycretin has shown promise: a recent study reported up to about 14.5 % weight loss and significant improvements in blood-sugar control (HbA1c reductions) over 36 weeks.
Since Amycretin combines two biological mechanisms, some experts believe it could become a “best-in-class” therapy, stronger than many existing drugs, and flexible too (injection or pill). Still, it’s important to note that Amycretin is not yet approved for general use. Late-stage (Phase 3) clinical trials are expected to begin in early 2026.
If everything goes well, Amycretin might offer a more powerful and convenient option for people struggling with obesity, a long-awaited next step beyond what’s available today.
What are your thoughts on the development of new drugs for weight loss? Do we really need them?
MBH/PS